Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results

Samardziski, Milan; Zafiroski, George; Tolevska, Cveta; Kalicanin-Markovska, M; Doncovska, Danica; Anevska, Vesna; Runceva, Mirjana

doi:10.2478/v10019-009-0019-7

Cited by 2 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there has been some evidence that in the treatment of lymphoma patients the better response is associated with the prolonged disease-free survival, the correlation between the quality of response and the survival still remains unknown 4–9. Recently published studies have indicated that a better response to first-line treatment translates into an improved survival for patients with follicular lymphoma and also with other malignomas 10,11. With our retrospective study we, therefore, wanted to assess the potential correlation between either the quality of response or the line of the rituximab treatment with both the overall survival (OS) and the disease-free survival (DFS) of patients with B-cell lymphomas.…”

Section: Introductionmentioning

confidence: 99%

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

Horvat¹,

Novaković²

2010

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundThe introduction of rituximab into the treatment of patients with non-Hodgkin’s lymphomas has improved the overall response rate, as well as the response duration and the overall survival of patients with B-cell lymphomas. But only a few studies have addressed the question whether the better response (complete response) and the early introduction of rituximab into the treatment translate into the better survival. The aim of this retrospective study was to assess the potential relationship between either the quality of the response or the line of the rituximab treatment and the overall survival (OS) as well as the disease-free survival (DFS) of patients with B-cell lymphomas.Patients and methods.In the study, we analysed treatment outcomes in patients with different histological types of B-cell lymphomas who were treated at the Institute of Oncology between 2003 and 2007 with rituximab and chemotherapy. We included only patients who had the level of CD20 expression assessed prior to the introduction of the treatment with quantitative flow-cytometric measurements. The OS and DFS were evaluated by Kaplan-Meier survival curves.ResultsOne hundred and fourteen patients were enrolled in the study. Patients who achieved a complete response after the rituximab containing treatment had a significantly longer OS than those reaching a partial response (hazard ratio [HR], 0.34; 95% CI, 0.05 to 0.91, P = 0.0375) and than patients with stable (hazard ratio [HR], 0.11; 95% CI, 0.0002 to 0.033, P < 0.0001) or progressive disease (hazard ratio [HR], 0.09; 95% CI, 0.003 to 0.03, P < 0.0001). Patients who achieved a complete response (CR; n = 70; 61.4%) had also a significantly longer DFS (hazard ratio [HR], 0.26; 95% CI, 0.021 to 0.538, P = 0.0068) than those reaching only a partial response (PR; n = 17; 14.9%). Patients treated with rituximab as the first-line treatment (n = 50; 43.9%) had a significantly longer OS than those treated with rituximab for the first (hazard ratio [HR], 0.27; 95% CI, 0.106 to 0.645, P = 0.0036) or second relapse (hazard ratio [HR], 0.22; 95% CI, 0.078 to 0.5, P = 0.0006). Also the DFS of patients treated with rituximab as the first-line treatment (n = 46; 52.9%) was significantly longer (hazard ratio [HR], 0.32; 95% CI, 0.088 to 0.9, P = 0.0325) than in patients treated with rituximab for their first relapse (n = 25; 28.7%).ConclusionsThese data indicate that a better response to rituximab therapy presumably translates into an improved OS and DFS for patients with B-cell lymphomas. The early introduction of rituximab into the treatment (i.e. first-line treatment) might improve OS. Therefore, the response adapted first-line therapy with rituximab should be considered when the treatment decision is taken in B-cell lymphoma patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

Horvat¹,

Novaković²

2010

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…The single most important factor influencing the outcome of patients with squamous cell carcinomas (SCC) of the upper aerodigestive tract is like at the other malignancies the stage of the disease at the time of initial diagnosis and treatment. [4][5][6] Once the tumour is no longer localized but has disseminated to regional lymph nodes, the probability of 5 year survival reduces to nearly half. [7][8][9] The patient's long-time prognosis is also worsened by the fact that the new primary SCC of upper aerodigestive tract occurred in 20% of these patients.…”

Section: Introductionmentioning

confidence: 99%

Influence of surgical treatment and radiotherapy of the advanced intraoral cancers on complete blood count, body mass index, liver enzymes and leukocyte CD64 expression

Dovšak¹,

Ihan²,

Didanović³

et al. 2009

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results

Cited by 2 publications

References 13 publications

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma

Influence of surgical treatment and radiotherapy of the advanced intraoral cancers on complete blood count, body mass index, liver enzymes and leukocyte CD64 expression

Contact Info

Product

Resources

About